# Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors

> **NCT01214668** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 31 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** LY573636-sodium
- **DRUG:** Liposomal Doxorubicin

## Key facts

- **NCT ID:** NCT01214668
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01214668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01214668, "Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01214668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*